CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
批准号:
9040904
负责人:
Christy Hagan
金额:
$24.9万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-23 至 2018-03-31
关键词:
BindingBinding ProteinsBinding SitesBiologyBreastBreast Cancer CellBreast Cancer PreventionBreast CarcinomaCancerousCarcinomaCell MaintenanceCell ProliferationCellsDUSP6 proteinDataDevelopmentDockingEstrogen ReceptorsEventGene Expression RegulationGene TargetingGenesGenetic TranscriptionGenomicsGoalsHyperplasiaKnockout MiceLigandsMaintenanceMammary NeoplasmsMammary glandMediatingMusN-terminalOvarian Steroid HormonePhosphorylationProgesteroneProgesterone ReceptorsProtein IsoformsProteinsRecruitment ActivityRegulationResearch ProposalsSerineSignal TransductionStat5 proteinStem cellsSteroid ReceptorsTissuesUterusbasebreast lesiongenetic signaturegenome-widehormone therapymalignant breast neoplasmmouse developmentnovelpreventprogesterone receptor Aprogesterone receptor Bpromoterreceptortumor progressionwhole genome
中文摘要
项目摘要
孕激素是一种对乳房发育至关重要的卵巢类固醇激素。孕激素受体(PR)
主要存在于两种共表达的同种型PR-A和PR-B中。对基因敲除小鼠的研究表明,
PR-B是乳腺腺泡形成过程中增殖信号传导所必需的。相反,需要PR-A
用于子宫发育,其中孕酮抑制增殖。对监管了解甚少
PR组织和亚型特异性转录。同种型特异性促有丝分裂(乳腺PR-B)和
是否达到抑制/分化(子宫中的PR-A)效应?PR-A和PR-B最常共表达于
相同的组织和细胞只表达一种PR亚型是罕见的,除了乳腺癌,
正常的1:1比例经常改变。选择性PR亚型抑制(阻断PR-B的促增殖作用)
同时保留PR-A的保护或抗增殖作用)将代表在以下方面的重大进展:
乳腺癌预防和/或治疗。PR是高度事后修改的。磷酸化,
主要作用于PR-B N-末端丝氨酸残基,显著改变受体的稳定性、定位、转录
活性和启动子选择性。我们的初步数据表明,PR-B特异性增殖的基础,
在乳腺癌细胞中的作用涉及CK2依赖性PR-B Ser81的选择性磷酸化,
蛋白质相互作用结构域,共同对接(CD)结构域,只在PR-B中发现,而不是PR-A。
PR-B Ser81的磷酸化调节增殖和促存活基因的高度特异性子集,
包括已知调节乳腺干细胞区室的所选PR调节基因,例如
Wnt1和STAT5A。此外,我们的数据表明,STAT5A可能作为一个"先锋因子",
募集/指导磷酸化Ser81-PR-B特异性基因调控的基因组结合配偶体。这个目标
研究计划是确定蛋白质如何通过CD结构域与PR-B相互作用,
PR-B在Ser81上的磷酸化,从而决定PR-B亚型特异性的基因转录事件
对于乳腺癌细胞增殖、促存活和干细胞区室的扩增是重要的。
假设:PR和STAT 5共调节磷酸化PR-B靶基因的特定亚组(通过CD结构域)。
MKP 3和ck2的依赖性募集,随后是ck2介导的PR-B Ser81的磷酸化),
调节乳腺癌细胞增殖和促存活,部分通过调节乳腺干细胞
所选基因在配体不存在的情况下由磷酸-PR-B调节。CK 2依赖
PR-B的活化可加速乳腺肿瘤的发展和/或驱动早期乳腺癌的进展。
英文摘要
Project Summary
Progesterone is an ovarian steroid hormone essential for breast development. The progesterone receptor (PR)
exists primarily in two co-expressed isoforms, PR-A and PR-B. Studies from knockout-mice have shown that
PR-B is required for proliferative signaling during mammary gland alveologenesis. In contrast, PR-A is required
for uterine development, where progesterone inhibits proliferation. Very little is understood regarding regulation
of PR tissue- and isoform-specific transcription. How are isoform-specific mitogenic (PR-B in the breast) and
inhibitory/differentiative (PR-A in the uterus) effects achieved? PR-A and PR-B are most often co-expressed in
the same tissues, and cells that express only a single PR isoform are rare, except in breast cancer where the
normal 1:1 ratio is frequently altered. Selective PR isoform inhibition (blocking pro-proliferative effects of PR-B
while preserving the protective or anti-proliferative effects of PR-A) would represent significant progress in
breast cancer prevention and/or treatment. PR is highly post-translationally modified. Phosphorylation,
primarily on PR-B N-terminal serine residues, significantly alters receptor stability, localization, transcriptional
activity and promoter selectivity. Our preliminary data suggest that the basis for PR-B-specific proliferative
actions in breast cancer cells involves ck2-dependent selective phosphorylation of PR-B Ser81 via a unique
protein interaction domain, the common docking (CD) domain, found exclusively in PR-B but not PR-A.
Phosphorylation of PR-B Ser81 regulates a highly specific subset of proliferative and pro-survival genes,
including selected PR-regulated genes known to modulate the mammary stem cell compartment, such as
Wnt1 and STAT5A. Additionally, our data suggest that STAT5A may serve as a “pioneer factor”, an early
genomic binding partner that recruits/directs phospho-Ser81-PR-B-specific gene regulation. The goal of this
research proposal is to determine how proteins that interact with PR-B via the CD domain regulate direct
phosphorylation of PR-B on Ser81, thereby dictating PR-B isoform-specific transcriptional events at genes
important for breast cancer cell proliferation, pro-survival, and expansion of the stem cell compartment.
Hypothesis: PR and STAT5 co-regulate a specific subset of phospho-PR-B target genes (through CD domain-
dependent recruitment of MKP3 and ck2, followed by ck2-mediated phosphorylation of PR-B Ser81) that
regulate breast cancer cell proliferation and pro-survival, in part via modulation of the mammary stem cell
compartment; selected genes are regulated by phospho-PR-B in the absence of ligand. ck2-dependent
activation of PR-B may accelerate mammary tumor development and/or drive early breast cancer progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Progesterone Receptor as a Novel Means to Increase Efficacy of Immune Checkpoint Inhibitors in Hormone Receptor Positive Breast Cancer
-
批准号:10512899
-
项目类别:
-
资助金额:$25.56万
-
财政年份:2022
-
负责人:Christy Hagan
-
依托单位:
CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
-
批准号:8531690
-
项目类别:
-
资助金额:$9.75万
-
财政年份:2012
-
负责人:Christy Hagan
-
依托单位:
CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
-
批准号:8278299
-
项目类别:
-
资助金额:$9.21万
-
财政年份:2012
-
负责人:Christy Hagan
-
依托单位:
海外基金